http://orcid.org/0000-0002-9293-9036
Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Raman Sharma, Rachel Batchelor & Jacqueline Sin. (2023) Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. Journal of Psychoactive Drugs 55:5, pages 612-630.
Read now
Read now
Debora Oliveira, Rodrigo Fontenele, Jeremy Weleff, Mehmet Sofuoglu & Joao P. De Aquino. (2023) Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review of Psychiatry 35:5-6, pages 377-396.
Read now
Read now
Alexandra Arenson, Cynthia I. Campbell & Ilan Remler. (2023) Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder – a narrative review. Journal of Addictive Diseases 0:0, pages 1-11.
Read now
Read now
Matthias Luz & Deborah C. Mash. (2021) Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse. Expert Opinion on Drug Metabolism & Toxicology 17:9, pages 1019-1022.
Read now
Read now
Articles from other publishers (28)
Jeremy Weleff, Julio C. Nunes, Gabriel P. A. Costa, Mehmet Sofuoglu, R. Ross MacLean & Joao P. De Aquino. (2024) From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder. British Journal of Clinical Pharmacology.
Crossref
Crossref
Kirsten CherianKenneth Shinozuka, Burton J. TabaacAlejandro ArenasBryce D. BeutlerViviana D. EvansChelsey FasanoOwen S. Muir. (2024) Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine. American Journal of Therapeutics 31:2, pages e133-e140.
Crossref
Crossref
Yu Kyung Lee, Mark S. Gold, Kenneth Blum, Panayotis K. Thanos, Colin Hanna & Brian S. Fuehrlein. (2024) Opioid use disorder: current trends and potential treatments. Frontiers in Public Health 11.
Crossref
Crossref
Judit Biosca-Brull, Genis Ona, Lineth Alarcón-Franco & Maria Teresa Colomina. (2024) A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets. Translational Psychiatry 14:1.
Crossref
Crossref
Genís Ona, Ingrid Reverte, Giordano N Rossi, Rafael G dos Santos, Jaime EC Hallak, Maria Teresa Colomina & José Carlos Bouso. (2023) Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. Journal of Psychopharmacology 37:12, pages 1190-1200.
Crossref
Crossref
Alessio Mosca, Stefania Chiappini, Andrea Miuli, Gianluca Mancusi, Maria Chiara Santovito, Francesco Di Carlo, Mauro Pettorruso, John M. Corkery, Carlos Canessa, Giovanni Martinotti & Massimo Di Giannantonio. (2023) Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A
Systematic Review of the Current Literature. Current Neuropharmacology 21:11, pages 2178-2194.
Crossref
Crossref
Mary G. Hornick & Ashley Stefanski. (2023) Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder. Frontiers in Pharmacology 14.
Crossref
Crossref
David G. T. Whitehurst, Cassandra Mah, Emanuel Krebs, Benjamin Enns, M. Eugenia Socias, Didier Jutras-Aswad, Bernard Le Foll & Bohdan Nosyk. (2023) Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada. Quality of Life Research 32:8, pages 2209-2221.
Crossref
Crossref
Rayyan Zafar, Maxim Siegel, Rebecca Harding, Tommaso Barba, Claudio Agnorelli, Shayam Suseelan, Leor Roseman, Matthew Wall, David John Nutt & David Erritzoe. (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Frontiers in Psychiatry 14.
Crossref
Crossref
Deborah C. Mash. (2023) IUPHAR – invited review - Ibogaine – A legacy within the current renaissance of psychedelic therapy. Pharmacological Research 190, pages 106620.
Crossref
Crossref
Borja J. Rodríguez‐Cano, Maja Kohek, Genís Ona, Miguel Ángel Alcázar‐Córcoles, Rafael G. dos Santos, Jaime E. C. Hallak & José Carlos Bouso. (2022) Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences. Drug and Alcohol Review 42:2, pages 401-414.
Crossref
Crossref
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, Giulia Abate, Sara Anna Bonini, Gregorio Peron, Emanuela Tirelli, Mariachiara Pucci, Giovanni Ribaudo, Erika Oselladore, Marika Premoli, Alessandra Gianoncelli, Daniela Letizia Uberti & Maurizio Memo. (2023) The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. International Journal of Molecular Sciences 24:2, pages 1329.
Crossref
Crossref
C. Dauré & L. Mallet. 2023. Les Addictions. Les Addictions
593
599
.
Bruno Ramos Gomes & Luis Fernando Tofoli. (2022) A sacred plant of neuronal effect: the use of ibogaine in addiction treatments in Brazil. Anthropology of Consciousness 33:2, pages 333-357.
Crossref
Crossref
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, Gabriela Morales-Lima, João Ariel Bonar Fernandes & Renato Filev. (2022) Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neuroscience 3, pages 100025.
Crossref
Crossref
Patrick Köck, Katharina Froelich, Marc Walter, Undine Lang & Kenneth M. Dürsteler. (2022) A systematic literature review of clinical trials and therapeutic applications of ibogaine. Journal of Substance Abuse Treatment 138, pages 108717.
Crossref
Crossref
Douglas L. Gourlay, Howard A. Heit & Andrew J. Smith. 2022. Clinical Pain Management. Clinical Pain Management
407
418
.
Thomas Knuijver, Arnt Schellekens, Maarten Belgers, Rogier Donders, Toon van Oosteren, Kees Kramers & Robbert Verkes. (2021) Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study. Addiction 117:1, pages 118-128.
Crossref
Crossref
Yu Kyung Lee, Mark S. Gold & Brian S. Fuehrlein. (2022) Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. Journal of the Neurological Sciences 432, pages 120094.
Crossref
Crossref
Kabir B. Nigam & Ananda K. Pandurangi. (2021) Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature. SN Comprehensive Clinical Medicine 3:6, pages 1385-1395.
Crossref
Crossref
Victor Distefano Wiltenburg, Dianne da Rocha Prado & Fúlvio Rieli Mendes. 2021. Drugs and Human Behavior. Drugs and Human Behavior
479
510
.
A Benjamin Srivastava, John J Mariani & Frances R Levin. (2020) New directions in the treatment of opioid withdrawal. The Lancet 395:10241, pages 1938-1948.
Crossref
Crossref
Bethea A. Kleykamp, Marta De Santis, Robert H. Dworkin, Andrew S. Huhn, Kyle M. Kampman, Ivan D. Montoya, Kenzie L. Preston, Tanya Ramey, Shannon M. Smith, Dennis C. Turk, Robert Walsh, Roger D. Weiss & Eric C. Strain. (2019) Craving and opioid use disorder: A scoping review. Drug and Alcohol Dependence 205, pages 107639.
Crossref
Crossref
Kelly E. Dunn, Andrew S. Huhn, Cecilia L. Bergeria, Cassandra D. Gipson & Elise M. Weerts. (2019) Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. Journal of Pharmacology and Experimental Therapeutics 371:2, pages 422-452.
Crossref
Crossref
Kendall L. Mores, Benjamin R. Cummins, Robert J. Cassell & Richard M. van Rijn. (2019) A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists. Frontiers in Pharmacology 10.
Crossref
Crossref
Soledad Marton, Bruno González, Sebastián Rodríguez-Bottero, Ernesto Miquel, Laura Martínez-Palma, Mariana Pazos, José Pedro Prieto, Paola Rodríguez, Dalibor Sames, Gustavo Seoane, Cecilia Scorza, Patricia Cassina & Ignacio Carrera. (2019) Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in Pharmacology 10.
Crossref
Crossref
Esther Blessing, Sanya Virani & John Rotrosen. 2020. Substance Use Disorders. Substance Use Disorders
167
202
.
Joseph P. Barsuglia, Martin Polanco, Robert Palmer, Benjamin J. Malcolm, Benjamin Kelmendi & Tanya Calvey. 2018. Psychedelic Neuroscience. Psychedelic Neuroscience
121
158
.